Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsNovo Nordisk's Ozempic may have a cardiovascular edge over Eli Lilly's Mounjaro, according to a new real-world study. Adults with type 2 diabetes who escalated their Ozempic dose to 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events compared to those who switched to Mounjaro. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.
Novo Nordisk is claiming a cardiovascular win over rival Eli Lilly in the fiercely contested diabetes and obesity drug market. A new real-world study found that adults with type 2 diabetes who escalated their Ozempic dose from 1 mg to 2 mg had a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared to those who switched to Lilly's Mounjaro (at doses up to 15 mg). The findings were unveiled at the European Association for the Study of Diabetes (EASD) annual meeting in Milan.
The analysis drew from a large dataset of over 636,000 adults, tracking medication patterns and outcomes over time. Most patients stuck with Ozempic 1 mg, while a smaller subset either escalated their dose or switched to Mounjaro — giving researchers a real-world look at how intensification strategies play out in clinical practice.
By the Numbers:
Why it matters: For clinicians managing type 2 diabetes patients already on Ozempic, this study suggests that escalating the dose — rather than switching to a competitor — may offer meaningful cardiovascular benefits. That said, as a real-world, non-randomized study, it carries inherent limitations, and head-to-head clinical trials would be needed to confirm these findings.
